Felien Morlion
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Felien Morlion has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andreja Rajkovic
Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering Ghent University Ghent Belgium
1 shared publication - Charlotte Grootaert
Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium
1 shared publication - Fuhua Li
College of Food Science, Southwest University, Chongqing 400715, China
1 shared publication - John Van Camp
Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium
1 shared publication - Julie De Munck
Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering Ghent University Ghent Belgium
1 shared publication - Katarina Magdalenic
SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering Ghent University Ghent Belgium
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 108 (3) , e70406
Benzothiazepane‐Based Curcumin Analogs Show Selective Effects on Respiration, Permeability, and Growth of Gut‐Liver (Co‐Culture) Cell Models
Curcumin, a natural polyphenol with anti‐cancer potential, faces limitations due to metabolic instability, and non‐specific toxicity. This study focused on four curcumin analogs (FM038, FM044, FM045, FM050) featuring oxobutenylidene‐substituted benzothiazepane cores bearing pyridinyl or furan substituents. We systematically evaluated their selective toxic effect on human colon (Caco‐2) and liver (HepG2) cells. This study reveals that structural modifications critically govern the selective cytotoxicity of curcumin analogs towards proliferating Caco‐2 and HepG2 cells. Treatment with analogs featuring pyridin‐2‐yl substituents (FM045/FM050) resulted in a slightly reduced potency towards Caco‐2 cells compared to curcumin, whereas FM044 (furan‐2‐yl) was non‐toxic and FM038 (pyridin‐3‐yl, methylated core) maintained similar activity. In contrast, direct exposure to proliferating HepG2 cells resulted in less cytotoxicity compared to the Caco‐2 cell line, which points to a cell‐specific mode‐of‐action in growing cells. When combined in a co‐culture, metabolites generated and/or transported by differentiated Caco‐2 cells significantly decreased HepG2 viability at an apical concentration of 15 μM. Efflux analysis of respiration and acidification showed that FM050 induced the strongest mitochondrial dysfunction in Caco‐2 cells, directly driving cytotoxicity, whereas HepG2 toxicity correlated with intrinsic detoxification capacity rather than mitochondrial disruption. A metabolic shift towards glycolysis was observed in both cell lines, indicating energy pathway modulation to a more dysfunctional phenotype. These findings highlight the dual role of structural optimization (e.g., methylation, heterocyclic substituents) for (cancer) cell‐specific bioactivity and colonic metabolism and may guide future development of curcumin‐based chemopreventive agents after in vivo validation and metabolite characterization.
- 21 September 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 108 (3) , e70406
Open AccessBenzothiazepane‐Based Curcumin Analogs Show Selective Effects on Respiration, Permeability, and Growth of Gut‐Liver (Co‐Culture) Cell Models
Curcumin, a natural polyphenol with anti‐cancer potential, faces limitations due to metabolic instability, and non‐specific toxicity. This study focused on four curcumin analogs (FM038, FM044, FM045, FM050) featuring oxobutenylidene‐substituted benzothiazepane cores bearing pyridinyl or furan substituents. We systematically evaluated their selective toxic effect on human colon (Caco‐2) and liver (HepG2) cells. This study reveals that structural modifications critically govern the selective cytotoxicity of curcumin analogs towards proliferating Caco‐2 and HepG2 cells. Treatment with analogs featuring pyridin‐2‐yl substituents (FM045/FM050) resulted in a slightly reduced potency towards Caco‐2 cells compared to curcumin, whereas FM044 (furan‐2‐yl) was non‐toxic and FM038 (pyridin‐3‐yl, methylated core) maintained similar activity. In contrast, direct exposure to proliferating HepG2 cells resulted in less cytotoxicity compared to the Caco‐2 cell line, which points to a cell‐specific mode‐of‐action in growing cells. When combined in a co‐culture, metabolites generated and/or transported by differentiated Caco‐2 cells significantly decreased HepG2 viability at an apical concentration of 15 μM. Efflux analysis of respiration and acidification showed that FM050 induced the strongest mitochondrial dysfunction in Caco‐2 cells, directly driving cytotoxicity, whereas HepG2 toxicity correlated with intrinsic detoxification capacity rather than mitochondrial disruption. A metabolic shift towards glycolysis was observed in both cell lines, indicating energy pathway modulation to a more dysfunctional phenotype. These findings highlight the dual role of structural optimization (e.g., methylation, heterocyclic substituents) for (cancer) cell‐specific bioactivity and colonic metabolism and may guide future development of curcumin‐based chemopreventive agents after in vivo validation and metabolite characterization.